Skip to content
← Full study record

NCT00006227 · MORE INFO

Limitations, agreements, and source contact

Paclitaxel in Treating Patients With Ovarian Stromal Cancer · Source last updated 2020-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
limitations And Caveats
description
The protocol listed an overall study accrual range of 30 to 37, therefore the study achieved this accrual range (n=31). One patient had an indeterminate response for the primary outcome.
point Of Contact
email
purdyc@nrgoncology.org
organization
NRG Oncology
phone
(716)845-1300
phone Ext
2296
title
Christopher Purdy on behalf of Mark Brady PhD
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
limitations And Caveats
description
The protocol listed an overall study accrual range of 30 to 37, therefore the study achieved this accrual range (n=31). One patient had an indeterminate response for the primary outcome.
point Of Contact
email
purdyc@nrgoncology.org
organization
NRG Oncology
phone
(716)845-1300
phone Ext
2296
title
Christopher Purdy on behalf of Mark Brady PhD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice